These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 20029169)

  • 1. Novel method to process cystic fibrosis sputum for determination of oxidative state.
    Hector A; Jonas F; Kappler M; Feilcke M; Hartl D; Griese M
    Respiration; 2010; 80(5):393-400. PubMed ID: 20029169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation.
    Downey DG; Brockbank S; Martin SL; Ennis M; Elborn JS
    Pediatr Pulmonol; 2007 Aug; 42(8):729-35. PubMed ID: 17588254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers.
    Smountas AA; Lands LC; Mohammed SR; Grey V
    Clin Biochem; 2004 Nov; 37(11):1031-6. PubMed ID: 15498533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis.
    Sagel SD; Kapsner RK; Osberg I
    Pediatr Pulmonol; 2005 Mar; 39(3):224-32. PubMed ID: 15635615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis.
    Sagel SD; Sontag MK; Wagener JS; Kapsner RK; Osberg I; Accurso FJ
    J Pediatr; 2002 Dec; 141(6):811-7. PubMed ID: 12461498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis.
    Döring G; Frank F; Boudier C; Herbert S; Fleischer B; Bellon G
    J Immunol; 1995 May; 154(9):4842-50. PubMed ID: 7722333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis.
    Reid DW; Misso N; Aggarwal S; Thompson PJ; Walters EH
    Respirology; 2007 Jan; 12(1):63-9. PubMed ID: 17207027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolastin aerosol therapy and sputum taurine in cystic fibrosis.
    Cantin AM; Berthiaume Y; Cloutier D; Martel M
    Clin Invest Med; 2006 Aug; 29(4):201-7. PubMed ID: 16986483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy.
    Colombo C; Costantini D; Rocchi A; Cariani L; Garlaschi ML; Tirelli S; Calori G; Copreni E; Conese M
    Pediatr Pulmonol; 2005 Jul; 40(1):15-21. PubMed ID: 15858808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
    Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
    Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sputum processing techniques in cystic fibrosis.
    Cai Y; Carty K; Gibson P; Henry R
    Pediatr Pulmonol; 1996 Dec; 22(6):402-7. PubMed ID: 9016474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil cell death, activation and bacterial infection in cystic fibrosis.
    Watt AP; Courtney J; Moore J; Ennis M; Elborn JS
    Thorax; 2005 Aug; 60(8):659-64. PubMed ID: 16061707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function.
    Eickmeier O; Huebner M; Herrmann E; Zissler U; Rosewich M; Baer PC; Buhl R; Schmitt-Grohé S; Zielen S; Schubert R
    Cytokine; 2010 May; 50(2):152-7. PubMed ID: 20181491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis.
    Ordoñez CL; Kartashov AI; Wohl ME
    J Pediatr; 2004 Nov; 145(5):689-92. PubMed ID: 15520781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
    Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
    Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylation of sputum mucins is altered in cystic fibrosis patients.
    Schulz BL; Sloane AJ; Robinson LJ; Prasad SS; Lindner RA; Robinson M; Bye PT; Nielson DW; Harry JL; Packer NH; Karlsson NG
    Glycobiology; 2007 Jul; 17(7):698-712. PubMed ID: 17392389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis.
    Dauletbaev N; Viel K; Buhl R; Wagner TO; Bargon J
    J Cyst Fibros; 2004 Jun; 3(2):119-24. PubMed ID: 15463894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on Sagel et al.
    Ren CL
    Pediatr Pulmonol; 2005 Sep; 40(3):275; author reply 276. PubMed ID: 16037925
    [No Abstract]   [Full Text] [Related]  

  • 19. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis.
    Downey DG; Martin SL; Dempster M; Moore JE; Keogan MT; Starcher B; Edgar J; Bilton D; Elborn JS
    Pediatr Pulmonol; 2007 Mar; 42(3):216-20. PubMed ID: 17238189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte chemoattractant chemokines in cystic fibrosis.
    Rao S; Wright AK; Montiero W; Ziegler-Heitbrock L; Grigg J
    J Cyst Fibros; 2009 Mar; 8(2):97-103. PubMed ID: 19000946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.